DE Burlo Group Inc. Purchases 630 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

DE Burlo Group Inc. grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,195 shares of the pharmaceutical company’s stock after purchasing an additional 630 shares during the quarter. Vertex Pharmaceuticals comprises approximately 2.8% of DE Burlo Group Inc.’s investment portfolio, making the stock its 12th largest position. DE Burlo Group Inc.’s holdings in Vertex Pharmaceuticals were worth $22,880,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Whalen Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $662,000. Creative Planning increased its stake in shares of Vertex Pharmaceuticals by 5.3% in the 2nd quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock valued at $37,084,000 after acquiring an additional 3,998 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Vertex Pharmaceuticals by 640.0% in the 2nd quarter. Blue Trust Inc. now owns 1,443 shares of the pharmaceutical company’s stock valued at $676,000 after acquiring an additional 1,248 shares in the last quarter. Mizuho Securities USA LLC increased its stake in shares of Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after acquiring an additional 57,497 shares in the last quarter. Finally, Manning & Napier Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $74,213,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $451.23 on Thursday. Vertex Pharmaceuticals Incorporated has a 52-week low of $346.29 and a 52-week high of $519.88. The stock’s 50-day simple moving average is $475.38 and its 200 day simple moving average is $472.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same period in the previous year, the business posted $3.67 EPS. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Citigroup initiated coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $575.00 price target for the company. Scotiabank boosted their price target on shares of Vertex Pharmaceuticals from $480.00 to $486.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Finally, Piper Sandler boosted their price target on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $499.12.

Insider Activity at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. This represents a 27.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. This represents a 12.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,445 shares of company stock worth $2,218,394. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.